KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Payables (2016 - 2025)

Biogen has reported Payables over the past 17 years, most recently at $432.0 million for Q4 2025.

  • Quarterly results put Payables at $432.0 million for Q4 2025, down 80.12% from a year ago — trailing twelve months through Dec 2025 was $432.0 million (down 80.12% YoY), and the annual figure for FY2025 was $432.0 million, down 80.12%.
  • Payables for Q4 2025 was $432.0 million at Biogen, up from $413.1 million in the prior quarter.
  • Over the last five years, Payables for BIIB hit a ceiling of $7.9 billion in Q4 2021 and a floor of $354.5 million in Q2 2024.
  • Median Payables over the past 5 years was $564.2 million (2022), compared with a mean of $2.7 billion.
  • Biggest five-year swings in Payables: skyrocketed 1954.89% in 2022 and later crashed 94.22% in 2023.
  • Biogen's Payables stood at $7.9 billion in 2021, then crashed by 93.75% to $491.5 million in 2022, then surged by 1393.69% to $7.3 billion in 2023, then plummeted by 70.4% to $2.2 billion in 2024, then plummeted by 80.12% to $432.0 million in 2025.
  • The last three reported values for Payables were $432.0 million (Q4 2025), $413.1 million (Q3 2025), and $408.4 million (Q2 2025) per Business Quant data.